Navigation Links
Relburn-Metabolomics to Outline Research Progress at BIO Investor Forum
Date:10/20/2015

WESTFIELD, N.J., Oct. 20, 2015 /PRNewswire/ -- Relburn-Metabolomics, Inc. announced that the Company has been selected to present at the annual BIO Investor Forum taking place in San Francisco from October 20-21, 2015.  BIO is the industry's premier organization focused on life science innovations.  The Forum routinely attracts key executives and venture investors with extensive experience in biotechnology and pharmaceuticals.

Relburn is an emerging life-science company focused on improving health for patients with metabolic and inflammatory diseases.  During the Company's presentation, Dr. Raymond P. Warrell, Jr., Chief Executive Officer, will provide an update of the Company's scientific, business and development activities, and will meet with potential investors and partners. Presentation information follows:

 Event:BIO-Investor ForumDate: Wednesday October 21, 2015 Time: 9:30 AM (Pacific Time) Location:Hilton Parc 55 Hotel Room:Balboa

 

About Relburn-Metabolomics

Relburn's lead program is focused on the development of transformational therapy for chronic gout – a disease whose prevalence is doubling every 10 years and currently afflicts 16 million subjects in major markets.  Gout is caused by excess uric acid (UA) in blood and connective tissues that leads to exquisitely painful and destructive arthritis, kidney failure, and possibly accelerated cardiovascular disease.  Standard treatment seeks to either reduce production or increase excretion of UA.  Unlike other anti-gout drugs, Relburn compounds exert bifunctional activities on both UA production and excretion.  Targeting enzymes that mediate these activities, Relburn compounds are markedly more potent than standard drugs and have demonstrated exceptional clinical activity.

Gout treatment is focused on reducing UA to a target serum level less than 6.0 mg/dL that is known to be beneficial.  The Relburn prototype drug – tested in more than 350 patients -- showed that serum UA routinely dropped to less than 1.0 mg/dL, even at low doses.  With this "clinical proof-of-concept", Relburn has synthesized compounds to further enhance clinical activity and reduce potential side-effects. This drug library is covered by patent applications that are exclusively owned by the Company.  Relburn believes its drugs may replace current 1st-line treatments for gout, thereby leading to meaningful improvement in patient well-being.

Further information about Relburn-Metabolomics, Inc. can be accessed at:  www.relburn.com.

About BIO Investor Forum

More information about the meeting can be accessed at: https://www.bio.org/events/conferences/14th-annual-bio-investor-forum

This press release may contain forward-looking statements with respect to business conducted by Relburn-Metabolomics, Inc. By their nature, forward-looking statements and forecasts involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future.  Such forward-looking statements include those that express plans, anticipation, intent, contingency, goals, targets, or future developments, and are not statements of historical fact.  The words "potentially", "anticipates", "believes", "expects", and similar expressions also identify forward-looking statements.  The Company does not undertake to update any forward-looking statements, and there are a number of factors that could cause actual results and developments to differ materially.

Relburn company information:  908-301-0103, info@relburn.com 


'/>"/>
SOURCE Relburn-Metabolomics, Inc.
Copyright©2015 PR Newswire.
All rights reserved


Related medicine technology :

1. Life Care Medical Devices Provides Mid-Year 2013 Corporate Review and Outlines Near-Term Corporate Milestones
2. Market Access Trends Report Outlines Eleven Major Trends Impacting The U.S. Healthcare System
3. Diabetes Technology Society Outlines Potential Post-clearance Surveillance Program To Address Inaccuracy Of Blood Glucose Monitors
4. Study Outlines How to Ensure the Effective Deployment of iPads among Managed Markets Teams in the Pharmaceutical Sector
5. Actavis Outlines Standalone Pharmaceutical Pipeline at Investor Meeting
6. Boston Scientific Outlines Growth And Expansion Strategy At 2015 Investor Day
7. Benchmarking Study Outlines How Effective Utilization of the iPad can Enhance Pharmaceutical Industry Interactions with Payers
8. Celsion Completes Integration of EGEN and Outlines Clinical Development Plan for GEN-1 IL-12 Immunotherapy Program
9. Global Information Online Market Research Portal Provides Complimentary Sample Service for Customers to Preview Reports by Global Industry Analysts
10. Edgemont Capital Completes Sale Of Vince & Associates Clinical Research
11. Research Team Publishes New Methods for Synthetic Generation of Influenza Vaccines
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2021)... ... March 29, 2021 , ... The University of Texas Health Science Center ... San Antonio Multispecialty and Research Hospital, a destination center for research and treatment of ... In a nod to the COVID-19 pandemic, the ceremony was held virtually. , William ...
(Date:3/30/2021)... ... March 29, 2021 , ... Iora Health ... primary care, has partnered with Devoted Health , one of the fastest-growing ... across Maricopa County and provides seniors with the highest-quality care and experience possible, ...
(Date:3/30/2021)... CITY (PRWEB) , ... March 29, 2021 , ... ... has joined the Vaccine Credential Initiative (VCI), a group bringing together leading health ... record of vaccination status, based on open, interoperable standards. By joining the VCI ...
Breaking Medicine Technology:
(Date:3/30/2021)... , ... March 29, 2021 , ... ... the 21st Century , A Virtual Workshop Presented by WCG FDAnews and Cerulean ... 4:30 pm EDT, https://wcg.swoogo.com/modern-sop-and-quality-systems , Are one’s SOPs written for the ...
(Date:3/30/2021)... ... March 29, 2021 , ... According to data released ... reproductive age (13-44) in need of publicly funded contraception live in counties impacted by ... Colorado’s 64 counties have lost some of their Title X resources. , The ...
(Date:3/30/2021)... ... March 29, 2021 , ... Health Literacy Innovations (HLI), a ... confusion due to low health literacy today announces a new partnership with the ... work with ACAP’s member Safety Net Health Plans, those that provide comprehensive health ...
(Date:3/30/2021)... ... ... Dr. Colin Campbell is proud to announce the 1 year anniversary in their new state ... internal medicine and is a primary care specialist who has been practicing for 23 years. ... keep South Jersey healthy one patient at a time. , “Over the past year, Dr. ...
(Date:3/30/2021)... ... March 30, 2021 , ... The COVID-19 ... and survivors; their families; and their caregivers. Crossroads4Hope is addressing the needs of ... emotional support system, MyGo2Support, which meets needs of people impacted by cancer, no ...
Breaking Medicine News(10 mins):